Dr Ekambar Kandimalla
Sr Director of Oligo Gene Therapy, GeneLeap Bio
Dr. Ekambar Kandimalla is an expert in nucleic chemistry, biochemistry and nucleic acid drug development. Dr. Kandimalla has about 30 years of industry experience in nucleic acid drug discovery and development, including antisense, siRNA, TLR agonists and antagonists. He is currently heading oligonucleotide therapeutics and mRNA chemistries at GeneLeap Bio. Prior to GeneLeap, Dr Kandimalla held leadership roles at Idera Pharmaceuticals (formerly Hybridon), ChemGenes and Exicure. He has published over 150 research articles, reviews, and book chapters and is a coinventor on over 300 published and issued patents worldwide.